Back Hepatitis C

Hepatitis C

AASLD 2013: AbbVie's Dual Interferon-free Combination Cures Genotype 1b Hepatitis C in 95%

A 2-drug combination of direct-acting antivirals developed by AbbVie achieved sustained virological response (SVR) in 95% of previously untreated patients with genotype 1b hepatitis C infection after 12 weeks of treatment, without the need for pegylated interferon or ribavirin, Eric Lawitz from the Texas Liver Institute reported Sunday at the 64th AASLD Liver Meeting in Washington, DC. In people who had failed to respond to a previous course of pegylated interferon and ribavirin, the same combination achieved SVR in 90%.

alt

AASLD 2013: Expanded Hepatitis C Screening Needed for Veterans, Baby Boomers, Pregnant Women

Two large studies of the "Baby Boom" generation in the U.S. suggest that at least 50,000 military veterans may have undiagnosed hepatitis C, and that around 80% of patients born between 1945 and 1965 receiving care through 4 large primary health care systems could be undiagnosed, according to presentations at the 64th AASLD Liver Meeting in Washington DC. Other research showed that screening pregnant women for hepatitis C on the basis of self-disclosed risk factors would have missed almost three-quarters infections in this population between 2003 and 2010.

alt

AASLD 2013: Simeprevir + Sofosbuvir Produces High Sustained Response Rates for Hard-to-treat Patients

A 12-week all-oral combination of simeprevir plus sofosbuvir led to sustained virological response in 93% of genotype 1 prior null responders with mild-to-moderate liver fibrosis, working as well as a longer course of treatment or triple therapy including ribavirin, according to late-breaking findings from the COSMOS trial presented this week at the 64thAASLD Liver Meeting in Washington, DC. The study also showed that 100% of treatment-naive patients and null responders with advanced fibrosis or cirrhosis achieved early sustained response at 4 weeks post-treatment using the same dual regimen.

alt

AASLD 2013: Liver Meeting Opens with a Focus on Hepatitis C

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting kicked off Saturday, November 2, with an overview for the media by AASLD president Gregory Fitz. With the first next-generation direct-acting antivirals (DAAs) poised to emerge from the pipeline, hepatitis C and its treatment have generated the most interest and excitement at the conference.

alt

AASLD Liver Meeting Starts this Weekend in Washington, DC

The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this Friday, running November 1-5 at the Walter E. Washington Convention Center in Washington, DC. The highlight of this year's meeting will be numerous presentations on next-generation direct-acting antivirals (DAAs) for hepatitis C, now in late stages of development, both as interferon add-ons and in interferon-free regimens.

alt

AASLD 2013: 100% of Hard-to-treat Patients Cured with Sofosbuvir/Ledipasvir + Ribavirin or GS-9669

Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced genotype 1 chronic hepatitis C patients with advanced liver fibrosis or cirrhosis, according to the latest findings from the ELECTRON trial presented yesterday at the 64th AASLD Liver Meeting in Washington, DC. A related analysis of previously untreated people without cirrhosis found that reducing treatment duration to 6 weeks led to relapses.

alt

FDA Advisory Committee Gives Positive Opinions on HCV Drugs Simeprevir and Sofosbuvir

The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) this week gave unanimous recommendations for approval of 2 next-generation direct-acting antivirals for hepatitis C, Janssen's simeprevir (formerly TMC435) and Gilead Science's sofosbuvir (formerly GS-7977 and PSI-7977).

alt

AASLD 2013: Veterans Study Supports CDC Recommendation to Screen Baby Boomers for Hep C

A study of more than 5.5 million U.S. veterans presented at the 64thAASLD Liver Meeting this week in Washington, DC, found that 10% of those born between 1945 and 1965 tested positive for hepatitis C virus (HCV) -- compared with just 1%-2% of older or younger individuals -- providing support for recent recommendations that everyone in this age group should be screened for HCV regardless of risk factors.

alt

EACS 2013: HCV Reinfection Common Among HIV Positive Gay Men in Europe

A study found that 18% of HIV positive men acquired hepatitis C virus (HCV) a second time after clearing the virus, with some having third and fourth infections as well, according to findings from the European AIDS Treatment Network presented at the 14th European AIDS Conference this month in Brussels.

alt